SB 203580是一种吡啶咪唑类p38 MAPK抑制剂(IC50=0.3-0.5 µM)。SB 203580抑制IL-2诱导的T细胞增殖（IC50=3-5 µM），激活人肝细胞中ERK和JNK的表达，并激活下游ERK-P、JNK-P和c-Jun-P表达。SB 203580参与多种炎症反应和细胞应激反应。另外，SB 203580通过抑制RIPK2表达从而降低DENV感染的HepG2细胞凋亡，并诱导人肝癌细胞自噬作用。在BALB/c小鼠中，SB 203580降低子宫内膜病变的重量和大小，并降低腹膜细胞中IL-1β、TNF-α、MMP-2和MMP-9 mRNA水平。

参考文献

[1] Lali FV, et al. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity,protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J BiolChem 275(10): 7395-7402 (2008).

[2]Crawley JB, et al. T Cell Proliferation in Response to Interleukins 2 and 7 Requires p38MAP Kinase Activation. J. Biol. Chem. 272: 15023–15027(1997).

[3] Zhang H, et al. Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK. Apoptosis 17(4):325-334 (2012).

[4] Sreekanth GP, et al. SB203580 Modulates p38 MAPK Signaling and Dengue Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2 Phosphorylation. PLoS ONE 11(2): e0149486 (2016).

[5] Henklova P, et al. SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes. European Journal of Pharmacology593 (1–3): 16–23 (2008).

[6] Zhou WD, et al. SB203580, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model. Hum. Reprod. 25 (12): 3110-3116(2010).

粉末直接保存于-20 ºC，有效期2年。溶于DMSO。建议分装后-20ºC避光保存，避免反复冻存，至少可存放6个月。

注意事项

1）为了您的安全和健康，请穿实验服并戴一次性手套操作。

2）粉末溶解前请先短暂离心，以保证产品全在管底。

3）本产品仅用于科研用途，禁止用于人身上。